By Lina carolina 
A groundbreaking advancement in the fight against childhood cancer has emerged from a pan-Canadian research collaboration, offering a novel and significantly faster approach to identifying personalized treatments for young patients. Researchers have successfully combined the power of proteomics—the study of proteins—with an innovative in-ovo tumor growth model, utilizing chicken eggs as "avatars" to rapidly test drug efficacy. This pioneering strategy has already demonstrated its potential by identifying a viable treatment option for a child with a rare and aggressive cancer that had resisted conventional therapies.
The initiative, spearheaded by a formidable team from the University of British Columbia (UBC) and the BC Children’s Hospital Research Institute (BCCHR), marks a significant first in Canada for integrating these two advanced techniques into a clinical workflow. The success of this approach, detailed in the latest issue of EMBO Molecular Medicine, underscores the critical role of proteomics as a dynamic complement to genomics in the real-time management of cancer.
This ambitious project is a cornerstone of PROFYLE (PRecision Oncology For Young peopLE), a vital component of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). ACCESS represents a monumental collaborative effort, uniting over 30 research and funding organizations and more than 100 investigators from across the nation. Its overarching mission is to dramatically improve cancer outcomes for children and young adults through coordinated research and enhanced survivorship care.
The specific study that heralded this breakthrough was co-led by Dr. Georgina Barnabas, a postdoctoral researcher in the laboratory of Dr. Philipp Lange, and Tariq Bhat, a PhD student under the supervision of Dr. James Lim. Their focus was on an unnamed pediatric patient diagnosed with an exceptionally rare form of cancer that had proven stubbornly resistant to all standard treatment protocols.
The Power of Proteomics in Uncovering Hidden Vulnerabilities
While genomics provides the genetic blueprint—the instructions for building cellular machinery—it is proteins that are the actual workhorses of our cells, carrying out virtually all biological functions. The vast majority of cancer drugs are designed to interact with and alter the activity of these proteins. Recognizing this fundamental principle, the research team hypothesized that a deeper analysis of a tumor’s protein landscape, or proteomics, could reveal critical weaknesses and dependencies that might be overlooked by genetic testing alone.
In the case of the young patient, initial genomic analysis had failed to pinpoint a clear therapeutic target. Following the failure of standard chemotherapy and the development of resistance to a drug selected via genomics, further genetic investigations yielded no promising avenues. It was at this juncture that the team pivoted to proteomics. This comprehensive protein analysis uncovered a striking reliance of the patient’s tumor on a specific enzyme, SHMT2 (serine hydroxymethyltransferase 2), a key player in the tumor’s metabolic pathways.
Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, alongside Dr. James Lim and clinician Dr. Rebecca Deyell, highlighted the limitations of solely relying on genomics in such complex cases. "With genomics alone, we couldn’t find a clear treatment option," Dr. Lange stated. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug."
This discovery led the researchers to identify sertraline, a widely prescribed antidepressant known for its efficacy in treating depression and anxiety, as a potential therapeutic agent. Sertraline functions by inhibiting SHMT2, thereby disrupting the tumor’s access to a crucial source of energy and hindering its growth.
Avian Models Accelerate Treatment Discovery
The critical challenge then became how to rapidly validate whether sertraline could indeed be effective against this specific tumor. Traditional methods of drug testing, such as laboratory cell cultures or animal models, can be time-consuming, often taking months to yield results. For a child with a rapidly progressing cancer, such a delay is unacceptable.
To overcome this hurdle, the team employed a sophisticated technique that involves implanting a small sample of the patient’s tumor onto the chorioallantoic membrane of a fertilized chicken egg. This creates a "tumor avatar" that grows outside the patient, effectively mimicking the tumor’s behavior in a controlled environment. This method, part of the BRAvE (Better Responses through Avatars and Evidence) initiative at BCCHR, which fosters crucial links between clinical care and research laboratories, allows for the rapid evaluation of drug responses within a matter of weeks.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," explained Dr. James Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour." The ability to grow an identical tumor outside the patient provided a unique opportunity to test the efficacy of sertraline in a personalized manner, offering a tangible preview of its potential impact.
A Collaborative Decision and Promising, Yet Incomplete, Results
The findings from the chicken egg avatar experiments were then presented to a panel of experts convened by PROFYLE. This multidisciplinary panel, comprising oncologists, researchers, and pharmacologists, rigorously evaluated the evidence. After careful deliberation, sertraline was identified as the most promising treatment option for the patient at that critical juncture.
Upon commencing treatment with sertraline, the patient’s tumor growth did indeed show a significant deceleration. However, the growth did not completely halt, indicating that while the drug was effective, it was not a complete cure and that additional therapeutic strategies would be necessary.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," Dr. Lange emphasized. "We now hope to expand this method to other children to identify effective treatments faster across the country."
Broader Implications and Future Directions
The success of this pan-Canadian initiative has profound implications for the future of pediatric oncology. It highlights a critical paradigm shift from a one-size-fits-all approach to highly personalized cancer care. By integrating advanced proteomic analysis with rapid, in-vivo drug testing models, researchers are forging a path towards more timely and effective interventions for children facing life-threatening cancers.
The collaborative nature of ACCESS and PROFYLE is also a testament to the power of national scientific networks. By pooling resources, expertise, and patient data, Canada is positioning itself at the forefront of precision medicine in pediatric cancer. The involvement of over 100 investigators and numerous institutions signifies a unified national commitment to tackling childhood cancers with innovative strategies.
The current success, while not a complete cure, represents a significant step forward. It demonstrates that even in the face of highly aggressive and resistant cancers, personalized approaches can identify viable treatment pathways. The next phase of this research will likely involve expanding the application of this combined proteomic and avatar-based strategy to a larger cohort of pediatric cancer patients. This will allow for the collection of more extensive data, further refining the methodology and potentially leading to the identification of novel drug targets and combinations.
Furthermore, the research team’s ability to repurpose an existing, approved drug like sertraline is particularly noteworthy. This strategy significantly reduces the time and cost associated with drug development, as the safety and pharmacokinetic profiles of such medications are already well-established. This makes personalized treatments more accessible and deployable in clinical settings.
The implications extend beyond just finding treatments. This approach has the potential to:
- Reduce treatment toxicity: By identifying drugs that specifically target tumor vulnerabilities, the collateral damage to healthy tissues can be minimized, leading to fewer side effects and improved quality of life for young patients.
- Accelerate clinical trials: The ability to rapidly screen potential drugs in avatar models could streamline the process of selecting candidates for clinical trials, getting promising therapies to patients faster.
- Enhance understanding of cancer biology: The detailed proteomic data generated from individual tumors can provide invaluable insights into the complex mechanisms driving different types of childhood cancers, paving the way for future discoveries.
- Foster international collaboration: As this model proves successful, it could serve as a blueprint for similar initiatives in other countries, creating a global network for accelerating pediatric cancer research.
The journey from genetic sequencing to proteomic analysis and then to rapid in-ovo drug testing represents a sophisticated, multi-layered approach to precision oncology. The ongoing work by the UBC, BCCHR, and their ACCESS/PROFYLE collaborators offers a beacon of hope for countless children and families affected by cancer, pushing the boundaries of what is possible in the fight for their futures. The integration of proteomics and innovative avatar technologies is not just a scientific advancement; it is a powerful demonstration of how scientific ingenuity, when coupled with dedicated collaboration, can directly translate into tangible benefits for the most vulnerable patients.
